Santhera Presents Positive Data from IONIA Open-Label Extension Study in Friedreich's Ataxia at the Fourth International Friedreich's Ataxia Scientific Conference

Liestal, Switzerland, May 5, 2011 – Santhera Pharmaceuticals (SIX: SANN) announced today that it will present positive data from an open-label extension study (IONIA-E) evaluating Ca-tena® for the treatment of Friedreich’s Ataxia. The findings indicate that Catena® can offer therapeutic benefit to pediatric patients by improving overall neurological function, particu-larly fine motor skills, and speech. Data will be presented by the principal investigator of the study, Dr. David Lynch from Children’s Hospital of Philadelphia (CHOP) on May 7 2011 in Strasbourg, France at the 4th International Friedreich’s Ataxia Scientific Conference [1].